TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03984786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICBT for alcohol misuse
Description: The 8-week internet-delivered cognitive behaviour therapy (ICBT) course for alcohol misuse. The course consists of 12 lessons distributed across 8 weeks (1 to 2 lessons a week).
Study: NCT02621814

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low glycation formula feeding
Description: Formula feeding on demand for 3 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Commercially common formula feeding
Description: Formula feeding on demand for 3 months
Study: NCT02374879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Glucose Monitoring Systems.
Description: In vitro diagnostic medical device.
Study: NCT00181961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maca Root
Study: NCT02665416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be provided as concentrate for solution to be administered via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selicrelumab
Description: Selicrelumab will be provided as concentrate for solution to be administered via SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanucizumab
Description: Vanucizumab will be provided as solution to be administered via IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered via IV infusion.
Study: NCT02152605

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
Study: NCT01373138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study: NCT04008004

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EDP-514
Study: NCT04019925

Intervention type: DEVICE
Group type: OTHER
Intervention: ADM/MDM hip
Description: Dual Mobility Hip prosthesis manufactured by Stryker Orthopaedics: ADM/MDM
Study: NCT00982800

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 200mg 3x/day for 3 days (9 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Study: NCT03229512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Topical 1% Sildenafil Cream
Study: NCT01373138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desloratadine and pseudoephedrine
Description: Desloratadine and pseudoephedrine 5/240 mg
Study: NCT02864992

Intervention type: DRUG
Group type: OTHER
Intervention: Tepotinib
Description: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Intervention type: DRUG
Group type: OTHER
Intervention: Tepotinib
Description: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Intervention type: DRUG
Group type: OTHER
Intervention: Tepotinib
Description: Subjects will receive 500 milligram (mg) of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Study: NCT05652114

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mightier
Description: Mightier is an app-based biofeedback video game that utilizes heart rate (HR) monitoring during game play to teach and facilitate practice of emotional regulation skills in children.
Study: NCT01654198

Intervention type: RADIATION
Intervention: FDG-PET/CT scan
Description: FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
Study: NCT00634998

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: 1000mg Vitamin C capsules orally twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1000mg Placebo capsules orally twice daily for 90 days
Study: NCT03019289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pridopidine (90 mg)
Description: single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 90 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
Study: NCT00537914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnitrope
Description: All enrolled patients received Omnitrope. The median daily dose varied between 0.0340 and 0.0351 mg/kg/day and the maximum range was 0.000 to 0.040 mg/kg/day over all visits.
Study: NCT00025376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor Biopsy
Study: NCT04053491

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand surgery under regional anesthesia
Description: In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand surgery under regional anesthesia
Description: In both groups, patients will benefit from an initial standardized bolus (long-acting local anesthetic, ropivacaine) to cover the operative period, via the allocated approach. Ultrasound guidance and the recommended standards monitors will be used in both groups. After the initial bolus, a catheter will be inserted via the allocated approach. Surgery will be done under regional anesthesia alone, unless there is a medical contraindication or if the patient asks for general anesthesia. Post-operative analgesia will be standardized with regular paracetamol, regular NSAID (Nonsteroidal anti-inflammatory drugs) and oxycodone if needed. The local anesthetics perfusion will be standardized. There will be a medical follow up at 24 and 48 hours where data will be collected.
Study: NCT01654315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomo Robotic Arm
Description: Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myomo Robotic Arm
Description: Patients are administered rehabilitative therapy (repetitive task specific therapy,, also known as RTP' in this study) using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period. These patients engage in RTP, which consists of a battery of activities that emphasize use of their affected arms repetitively, with the device providing assistance as needed with movement through the arm's range of motion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RTP Standard Therapy
Description: Active Comparator: RTP Group Patients are administered rehabilitative therapy using only RTP that is targeting their affected arms on 3 days/week during a 8 week period. In this condition, patients engage in activities that emphasize use of their affected arms repetitively, with the therapist providing assistance as needed with movement through the arm's range of motion. As patients progress, the amount of assistance provided by the therapist during the activities is reduced.
Study: NCT03209895

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Joint Health Product
Description: Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Palm oil Softgel capsule

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine / Chondroitin
Description: Glucosamine 1500 mg, Chondroitin 1200 mg per day
Study: NCT04343131

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Crossover dietary manipulation using three different types of diet for 7 days each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Crossover dietary manipulation using three different types of diet for 7 days each

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Crossover dietary manipulation using three different types of diet for 7 days each
Study: NCT00115453

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: irradiation
Description: Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
Study: NCT03570801

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert Panel Review
Description: There is some preliminary evidence suggesting that having a group of spinal experts review x-rays prior to treatment might provide useful information to the patient and the patients' treating physician when trying to make a decision about what type of surgery to perform.
Study: NCT02684149

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: relational touch

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: relational touch
Study: NCT02435732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo saline solution
Description: saline solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo saline solution
Description: saline solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo saline solution
Description: saline solution
Study: NCT01669083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 10 mg
Description: 10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 150 mg
Description: 150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 dose 3
Description: Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK557296 dose 4
Description: Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
Study: NCT02413489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
Study: NCT03342664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artemis + Medical Management
Description: Subject will receive best MM in addition to the MIS procedure with Artemis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Management Alone (MM)
Description: Subject will receive best MM for ICH as determined by stroke physician following AHA/ESO guidelines.
Study: NCT00313612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Given IV
Study: NCT01623596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Disease Modifying therapy
Study: NCT02435732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Added to the one of the arms receiving 200U/kg dose of CINRYZE

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: 200U/kg IV dose with or without heparin, or 500U/kg IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CINRYZE
Description: 200U/kg IV dose with or without heparin, or 500U/kg IV dose
Study: NCT00489216

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at~1mg/kg
Study: NCT00298727

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SHIPS
Description: Stakeholder-Hosted Interactive Problem-based Seminars

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ePBL
Description: Online Problem-Based Course
Study: NCT00587860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: St. John's wort
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
Study: NCT03953794

Intervention type: DEVICE
Intervention: Fitbit Charge 3
Description: Smart watch monitoring activity and movement, heart rate, sleep, and more
Study: NCT00160147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bifeprunox
Description: One week titration with dose adjustments
Study: NCT01627678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-C5/GM-CSF
Description: Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vacc-C5/Alhydrogel
Description: Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
Study: NCT00160147

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06040021

Intervention type: OTHER
Intervention: standardized treatment
Description: Patients enrolled in these 2 cohorts all received standardized treatment of colorectal cancer.
Study: NCT05952388

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Behavioral Patient care
Description: chart review
Study: NCT04346446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma Transfusion
Description: Convalescent Plasma Transfusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Supportive Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Care
Description: Supportive Care
Study: NCT04346446

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Random Donor Plasma
Description: Random Donor Plasma will be transfuse from 200 to 600 mL according to the patient requirement
Study: NCT02315131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Study: NCT02315131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
Study: NCT01432470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
Study: NCT02315131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV46017
Description: TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02044913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone-based Aftercare-Coordination
Description: After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
Study: NCT00765063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fragmin
Description: Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
Study: NCT00988949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04455242
Description: Single oral 18 mg dose of PF-04455242.
Study: NCT01735435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry
Description: The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.~IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes.
Study: NCT03528447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: Aerobic training:The aerobic exercise program consists of treadmill walking, cycle ergometer and arm ergometer training. Group exercises were performed in sets of 15 minutes each with three exercise modalities.~Strength training:It is recommended that resistance targets are set at loads equivalent to 20 to 40% of a 1-repetition maximum (1RM) maneuver and performed between 8 to 12 repetitions for 1 to 2 sets per session.~Home exercise programme:The program included breathing exercises (local expansion exercises, diaphragmatic breathing and pursed lip breathing), free walking, upper and lower extremity strengthening exercises with Thera-Band.
Study: NCT04222400

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Frailty Assessment
Description: Bioelectrical Impedance Analysis 6 Minute Walk Test Grip Strength Questionnaires Muscle Mass Evaluation via CT
Study: NCT01432470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
Study: NCT01579994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib (STA-9090) and crizotinib
Description: Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
Study: NCT04606862

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morley Medical Sepsis Software Device
Description: The Morley Medical Sepsis (MMS) Software Device is a predictive analytics, stand-alone, cloud-based software system with no hardware components. The software acquires patient data from the electronic medical record, processes the data using unique artificial intelligence (AI) powered algorithms, and generates clinical decision support outputs that aid in the proactive delivery of customized and efficient care for patients. The software output is made available to the end users (trained medical professionals) via an intuitive user interface displayed on desktop computers or mobile communication devices such as laptops, smartphones or tablets.
Study: NCT01753765

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Cryo-Touch III Study treatment at Day 0.
Description: Device: Cryo-Touch III Study treatment at Day 0.
Study: NCT03159052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR3824
Description: Once daily, 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily, 24 weeks
Study: NCT02073292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: c-RFA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: tRFA